Background/Aims: The purpose of this study was to examine the clinical features of metastatic tumors of the pancreas (MTPs) in Korea. Methods: A total of 53 cases (31 males) of pathologically proven MTPs were collected. Clinicopathological characteristics and patient outcomes were evaluated. Results: The median age at the diagnosis of the MTP was 60 years. The median interval between the diagnoses of primary malignancy and MTP was 2.2 years. Primary malignancies were renal cell carcinoma (RCC) (n=14), gastric cancer (n=11), colorectal cancer (n=5), lymphoma (n=4), non-small cell lung cancer (n=3), gastrointestinal stromal tumor (n=2), melanoma (n=2), small cell lung cancer (n=2), gallbladder cancer (n=2), hepatocellular carcinoma (n=1), thymic carcinoid (n=1), liposarcoma (n=1), cholangiocarcinoma (n=1), osteosarcoma (n=1), breast cancer (n=1), duodenal cancer (n=1), and ovarian cancer (n=1). The median survival after the diagnosis of MTP was 23.1 months. Multivariate analysis showed that prolonged survival was associated with RCC as the primary malignancy, the patient being asymptomatic upon the diagnosis of MTP, the absence of extrapancreatic involvement, and surgery included in the treatment. Conclusions: MTPs can occur after a prolonged period from the primary diagnosis. RCC as the primary malignancy, the patient being asymptomatic upon the diagnosis of MTP, the absence of extrapancreatic involvement, and surgery included in the treatment are associated with better prognosis. (Gut Liver 2011;5:61-64) 
INTRODUCTION
Metastatic tumors of the pancreas (MTPs) account for 3 to 16% of pancreatic malignancies. In most cases, they are part of a systemic metastasis, 1 hence the prognosis is poor. 2 MTPs are reported to occur with similar frequencies between men and women. They occur usually in the 6th decade. 1 Renal cell carcinoma (RCC), lung cancer, colorectal cancer, melanoma, and breast cancer are known to metastasize to the pancreas.
2-4
Presenting symptoms or signs of MTPs can be abdominal pain, jaundice, diabetes, or acute pancreatitis. 1 In contrast to pancreatic ductal adenocarcinoma, aggressive surgical interventions in cases with metastasis confined to the pancreas are known to offer better prognosis, especially in RCC.
3-5
A previous report by the authors reported 25 cases of pathologically confirmed MTPs in Korea. 6 The purpose of this study is to evaluate the clinical features and prognosis of MTPs with updating the authors' experience in a single center. The current report evaluates 53 patients with pathologically confirmed MTPs over a period of 13 years.
MATERIALS AND METHODS
We collected 53 patients who were diagnosed as MTPs with pathological confirmation in Seoul National University Hospital from January of 1997 to December of 2009. Patients were excluded when direct invasion from the primary malignancy was confirmed on imaging or intraoperatively. Gender, primary malignancy, age at the diagnosis of primary malignancy, age at the diagnosis of MTP, symptoms or signs upon the diagnosis of MTP, time interval between the diagnoses of primary tumor and pancreatic metastasis, location of the pancreatic metastasis, number of pancreatic metastases, extrapancreatic involvement, treatment after the diagnosis of MTP, and survival after the diagnosis of MTP were evaluated. The endpoints of this study were patient death or March 31st, 2010. This retrospective study was carried out in accordance with the ethical guidelines Median survival was estimated using the Kaplan-Meier method. Factors associated with prolonged survival were determined using the log-rank test. For factors of age at primary tumor diagnosis, gender, and those associated with prolonged survival in univariate analysis at p<0.25 were included as covariates in the Cox regression. Values are reported as median. Two-sided p-values of <0.05 were considered statistically significant. All analyses were done using SPSS for Windows version 11.0 (SPSS Inc., Chicago, IL, USA).
RESULTS

Clinicopathological characteristics
Thirty-one patients were male, and 22 patients were female. The median age at the diagnosis of the primary malignancy was 53 (range, 23-76) years. The most common primary malignancies were RCC (n=14) and gastric cancer (n=11). The primary malignancies are summarized in Table 1 . The median followup period after the diagnosis of MTP was 10.4 (range, 0-105.8) months.
The median age at the diagnosis of MTP was 60 (range, 25-76) years. MTPs were diagnosed synchronously in 15 patients (28.3%), 2 of whom were diagnosed on autopsy. The median interval between the diagnosis of primary malignancy and the diagnosis of MTP was 2.2 (range, 0-14.2) years. Of the 38 patients who were diagnosed metachronously, 22 were diagnosed during follow-up for the primary malignancy without any symptoms or signs. Eight patients presented with jaundice, 8 with abdominal pain, 4 with weight loss, 1 with upper GI bleeding, 1 with acute pancreatitis, and 3 laboratory abnormalities other than hyperbilirubinemia.
The locations of MTPs were head (n=23), body (n=8), tail (n=14), body and tail (n=4), head and tail (n=1), and diffuse involvement of the head, body, and tail (n=3). Forty-five patients had single lesions in the pancreas, and 8 patients (7 patients with RCC and 1 with lymphoma) had multiple pancreatic lesions. Extrapancreatic involvements of metastatic cancer were observed in 32 patients; the primary malignancies of these patients were RCC (n=6), gastric cancer (n=6), colorectal cancer (n=4), lymphoma (n=3), gastrointestinal stromal tumor (n=2), melanoma (n=2), small cell lung cancer (n=2), non-small cell lung cancer (n=2), liposarcoma (n=1), breast cancer (n=1), gallbladder cancer (n=1), duodenal cancer (n=1), and ovarian cancer (n=1).
Treatment and survival
After the diagnosis of MTP, 16 patients underwent chemotherapy, 15 surgery with chemotherapy, 11 surgery, 3 surgery and chemoradiation, 1 radiation therapy, 1 chemoradiation, and 6 palliative care. In 29 patients who had surgery included in their treatment, 14 underwent distal pancreatectomy, 11 pancreaticoduodenectomy, 2 median pancreatectomy, 1 palliative bypass, and 1 mass excision. Indications for surgery were isolated MTP in 10 cases, simultaneous pancreatic resection during surgery for primary tumor in 7, preoperative diagnosis of primary pancreatic cancer in 5, debulking of mass in 3, palliative procedure in 3, and preoperative diagnosis of primary duodenal tumor in 1. The median survival after the diagnosis of MTP estimated by the Kaplan-Meier method (excluding the 2 patients diagnosed on autopsy) was 23.1 months (Fig. 1) . 
